Industry News
Biotechnology Industry News

Corbus Pharmaceuticals’ phase 1b…
Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The biotech plans to enter phase 2.
Electra Therapeutics is hoping to…
Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug ipsoprubart.
Cellectis may have kicked off the…
Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
MediLink has reported phase 3…
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survival fell short of the bar set by GSK’s
Definium Therapeutics has scored a…
Definium Therapeutics has scored a third straight phase 3 win for its LSD formula, with the psychedelic significantly alleviating anxiety symptoms and setting up an FDA filing next year.
Cullinan Therapeutics and Taiho…
Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the front-line setting.
After decades of hard-won…
After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full heterogeneity of the disease.
Revolution Medicines recently made…
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.
BioNTech has linked gotistobart to…
BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
GSK’s risvutatug rezetecan has…
GSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.
Officials rubbed shoulders with…
Officials rubbed shoulders with business leaders in a 19th-floor meeting room to celebrate the launch of Singapore’s newest Overseas Centre.
Is the cancer truly gone? …
Is the cancer truly gone?
Takeda President of Research and…
Takeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.
The FDA has put enrollment in…
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests, dealing a blow to an asset covered by a pending $350 million deal.
Frazier Life Sciences (FLS) has…
Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.
Andy Plump, M.D., Ph.D., president…
Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.
It may have seemed like an…
It may have seemed like an ordinary Wednesday afternoon at MassBio’s headquarters in Technology Square, but the black SUV parked outside was a telltale sign that the Cambridge, Massachusetts-based biotech trade group was playing host
Following a steady stream of…
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.
The future of NAMs depends on more…
The future of NAMs depends on more than innovation. Learn how sourcing, standards and evidence can accelerate adoption.
Luma Group announced the final…
Luma Group announced the final close of its inaugural life sciences venture capital fund totaling $410 million.

